PLCG1 and cancer: Altogether our data show for the first time that the PDK1/PLCγ1 interaction is pharmacologically targetable and that its inhibition may have anti-metastatic effects in vivo. Therefore, 2-O-Bn-InsP5 could potentially be a promising anti-cancer lead compound to design novel anti-metastatic drugs.